Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025 after market close.

The company will host a conference call and webcast at 5:00 PM ET. Investors can access the live webcast through the company's IR website, or join via phone using the dial-in numbers: 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be available until September 6, 2025.

Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, announced inducement grants for two newly hired senior executives. The company's Human Capital Management and Compensation Committee has awarded 421,349 time-based restricted stock units (RSUs) each to Jeannine Lombardi, the new Chief Human Resource Officer, and Jonathan Paris, the new Chief Legal Officer.

The RSUs were granted on July 1, 2025, under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan. The vesting schedule includes 25% vesting on July 1, 2026, followed by quarterly installments of 6.25% over the subsequent three years, subject to continued employment.

Definitive Healthcare (DH) announced the granting of an inducement award to its new Chief Commercial Officer, Tina Hannagan, consisting of 830,565 time-based restricted stock units (RSUs). The award, granted on June 1, 2025, was approved by the company's Human Capital Management and Compensation Committee as part of Hannagan's employment agreement. The RSUs will vest over a four-year period, with 25% vesting on June 1, 2026, followed by quarterly installments of 6.25% over the subsequent three years. The grant was made under Definitive Healthcare's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare (NASDAQ: DH) reported Q1 2025 financial results with revenue of $59.2 million, down 7% from Q1 2024. The company posted a net loss of $(155.1) million, largely due to goodwill impairment charges of $176.5 million. Adjusted EBITDA was $14.7 million (25% of revenue), compared to $20.0 million (32%) in Q1 2024. Despite macroeconomic uncertainty, DH secured notable customer wins including a medical device company, a regional health system, and a leading office supply company. The company raised its full-year 2025 revenue guidance to $234.0-$240.0 million, with expected adjusted EBITDA of $61.0-$65.0 million.

Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence leader, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results.

Investors can access the live audio webcast on the company's IR website at https://ir.definitivehc.com/. A dial-in option is available at 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be accessible through June 7, 2025, using 800-645-7964 (domestic) or 757-849-6722 (international) with passcode 1765#.

Definitive Healthcare (Nasdaq: DH) has announced the granting of inducement awards to its newly hired senior leader. The company's Human Capital Management and Compensation Committee approved inducement awards for Jeff Moyer, who joins as SVP of Growth and Sales Operations.

The awards include 364,432 time-based restricted stock units (RSUs), effective April 3, 2025. The RSUs will vest according to the following schedule: 25% on April 1, 2026, with the remaining amount vesting in quarterly installments of 6.25% over the subsequent three years. These awards were granted under Definitive Healthcare's 2023 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare (Nasdaq: DH) announced inducement awards for two newly hired senior leaders. The company granted 172,414 time-based restricted stock units (RSUs) to Kate Hastings, the new Chief Customer Officer, and 1,018,330 RSUs to Benjamin Graboske, the new EVP, Technology, Engineering and Chief Data Officer, both effective March 3, 2025.

The awards, granted under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan, feature a vesting schedule where 25% vests initially (February 1, 2026 for Hastings; April 1, 2026 for Graboske), with the remainder vesting quarterly at 6.25% over three years, subject to continued employment.

Definitive Healthcare (DH) reported mixed Q4 and full-year 2024 results. Q4 revenue declined 6% to $62.3 million, while full-year revenue slightly increased to $252.2 million. The company recorded significant goodwill impairment charges of $97.1 million in Q4 and $688.9 million for the full year.

Q4 highlights include: Net Loss of $(84.7) million, Adjusted Net Income of $12.6 million, and Adjusted EBITDA of $17.5 million (28% margin). Full-year metrics showed improvement in cash flow operations, up 41% to $58.2 million, and Unlevered Free Cash Flow increased 6% to $72.5 million.

The company announced Casey Heller will become CFO effective June 2, 2025. For 2025, DH projects revenue between $230.0-$240.0 million and Adjusted EBITDA of $61.0-$65.0 million with 26-28% margin.

Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the upcoming Raymond James 2025 Institutional Investors Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time.

Investors and interested parties can access the live presentation through a webcast available on the Events page of Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. A recorded version of the presentation will be accessible for a time after the event.